Evidence shows prolonged oestrogen-progestin therapy elevates breast cancer risk compared to oestrogen-only use. Dr Neha Singh, health journalist, highlights that duration, dosage, individual health greatly influence outcomes. Women discontinuing therapy often observe risk reduction over time. Clinical monitoring and lifestyle modification remain key in ensuring safe HRT management post-menopause.